Market Analysis and Insights: Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market
The global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market size is projected to reach US$ 7965.2 million by 2026, from US$ 5341 million in 2020, at a CAGR of 6.9% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market.
Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Breakdown Data by Type
PCR
In-situ Hybridization
Immunohistochemistry
Sequencing
Others
Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Breakdown Data by Application
Oncology
Neurological Disorders
Cardiovascular Disease
Immunological Disorders
Others
Based on regional and country-level analysis, the Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market has been segmented as follows:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
In the competitive analysis section of the report, leading as well as prominent players of the global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
The following players are covered in this report:
Qiagen NV
GE Healthcare
Agilent Technologies
F Hoffman La Roche
Foundation Medicine
Thermo Fisher Scientific Inc.
Leica Biosystems Nussloch GmBH
Pfizer
The global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market size is projected to reach US$ 7965.2 million by 2026, from US$ 5341 million in 2020, at a CAGR of 6.9% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market.
Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Breakdown Data by Type
PCR
In-situ Hybridization
Immunohistochemistry
Sequencing
Others
Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Breakdown Data by Application
Oncology
Neurological Disorders
Cardiovascular Disease
Immunological Disorders
Others
Based on regional and country-level analysis, the Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market has been segmented as follows:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
In the competitive analysis section of the report, leading as well as prominent players of the global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
The following players are covered in this report:
Qiagen NV
GE Healthcare
Agilent Technologies
F Hoffman La Roche
Foundation Medicine
Thermo Fisher Scientific Inc.
Leica Biosystems Nussloch GmBH
Pfizer
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Growth Rate by Type: 2020 VS 2026
1.2.2 PCR
1.2.3 In-situ Hybridization
1.2.4 Immunohistochemistry
1.2.5 Sequencing
1.2.6 Others
1.3 Market by Application
1.3.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Share by Application: 2020 VS 2026
1.3.2 Oncology
1.3.3 Neurological Disorders
1.3.4 Cardiovascular Disease
1.3.5 Immunological Disorders
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Perspective (2015-2026)
2.2 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Growth Trends by Regions
2.2.1 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Historic Market Share by Regions (2015-2020)
2.2.3 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Players by Market Size
3.1.1 Global Top Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Players by Revenue (2015-2020)
3.1.2 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Share by Players (2015-2020)
3.2 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue
3.4 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Concentration Ratio
3.4.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue in 2019
3.5 Key Players Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Area Served
3.6 Key Players Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Product Solution and Service
3.7 Date of Enter into Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Breakdown Data by Type (2015-2026)
4.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Historic Market Size by Type (2015-2020)
4.2 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Forecasted Market Size by Type (2021-2026)
5 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Breakdown Data by Application (2015-2026)
5.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Historic Market Size by Application (2015-2020)
5.2 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size (2015-2026)
6.2 North America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Type (2015-2020)
6.3 North America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application (2015-2020)
6.4 North America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Country (2015-2020)
6.4.1 United States
6.4.2 Canada
7 Europe
7.1 Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size (2015-2026)
7.2 Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Type (2015-2020)
7.3 Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application (2015-2020)
7.4 Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Country (2015-2020)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
7.4.6 Nordic
7.4.7 Rest of Europe
8 China
8.1 China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size (2015-2026)
8.2 China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Type (2015-2020)
8.3 China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application (2015-2020)
8.4 China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Region (2015-2020)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 Southeast Asia
8.4.5 India
8.4.6 Australia
8.4.7 Rest of Asia-Pacific
9 Japan
9.1 Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size (2015-2026)
9.2 Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Type (2015-2020)
9.3 Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application (2015-2020)
9.4 Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Country (2015-2020)
9.4.1 Mexico
9.4.2 Brazil
10 Southeast Asia
10.1 Southeast Asia Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size (2015-2026)
10.2 Southeast Asia Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Type (2015-2020)
10.3 Southeast Asia Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application (2015-2020)
10.4 Southeast Asia Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Country (2015-2020)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 UAE
10.4.4 Rest of Middle East & Africa
11 Key Players Profiles
11.1 Qiagen NV
11.1.1 Qiagen NV Company Details
11.1.2 Qiagen NV Business Overview
11.1.3 Qiagen NV Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Introduction
11.1.4 Qiagen NV Revenue in Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Business (2015-2020))
11.1.5 Qiagen NV Recent Development
11.2 GE Healthcare
11.2.1 GE Healthcare Company Details
11.2.2 GE Healthcare Business Overview
11.2.3 GE Healthcare Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Introduction
11.2.4 GE Healthcare Revenue in Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Business (2015-2020)
11.2.5 GE Healthcare Recent Development
11.3 Agilent Technologies
11.3.1 Agilent Technologies Company Details
11.3.2 Agilent Technologies Business Overview
11.3.3 Agilent Technologies Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Introduction
11.3.4 Agilent Technologies Revenue in Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Business (2015-2020)
11.3.5 Agilent Technologies Recent Development
11.4 F Hoffman La Roche
11.4.1 F Hoffman La Roche Company Details
11.4.2 F Hoffman La Roche Business Overview
11.4.3 F Hoffman La Roche Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Introduction
11.4.4 F Hoffman La Roche Revenue in Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Business (2015-2020)
11.4.5 F Hoffman La Roche Recent Development
11.5 Foundation Medicine
11.5.1 Foundation Medicine Company Details
11.5.2 Foundation Medicine Business Overview
11.5.3 Foundation Medicine Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Introduction
11.5.4 Foundation Medicine Revenue in Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Business (2015-2020)
11.5.5 Foundation Medicine Recent Development
11.6 Thermo Fisher Scientific Inc.
11.6.1 Thermo Fisher Scientific Inc. Company Details
11.6.2 Thermo Fisher Scientific Inc. Business Overview
11.6.3 Thermo Fisher Scientific Inc. Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Introduction
11.6.4 Thermo Fisher Scientific Inc. Revenue in Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Business (2015-2020)
11.6.5 Thermo Fisher Scientific Inc. Recent Development
11.7 Leica Biosystems Nussloch GmBH
11.7.1 Leica Biosystems Nussloch GmBH Company Details
11.7.2 Leica Biosystems Nussloch GmBH Business Overview
11.7.3 Leica Biosystems Nussloch GmBH Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Introduction
11.7.4 Leica Biosystems Nussloch GmBH Revenue in Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Business (2015-2020)
11.7.5 Leica Biosystems Nussloch GmBH Recent Development
11.8 Pfizer
11.8.1 Pfizer Company Details
11.8.2 Pfizer Business Overview
11.8.3 Pfizer Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Introduction
11.8.4 Pfizer Revenue in Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Business (2015-2020)
11.8.5 Pfizer Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Growth Rate by Type: 2020 VS 2026
1.2.2 PCR
1.2.3 In-situ Hybridization
1.2.4 Immunohistochemistry
1.2.5 Sequencing
1.2.6 Others
1.3 Market by Application
1.3.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Share by Application: 2020 VS 2026
1.3.2 Oncology
1.3.3 Neurological Disorders
1.3.4 Cardiovascular Disease
1.3.5 Immunological Disorders
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Perspective (2015-2026)
2.2 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Growth Trends by Regions
2.2.1 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Historic Market Share by Regions (2015-2020)
2.2.3 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Players by Market Size
3.1.1 Global Top Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Players by Revenue (2015-2020)
3.1.2 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Share by Players (2015-2020)
3.2 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue
3.4 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Concentration Ratio
3.4.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue in 2019
3.5 Key Players Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Area Served
3.6 Key Players Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Product Solution and Service
3.7 Date of Enter into Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Breakdown Data by Type (2015-2026)
4.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Historic Market Size by Type (2015-2020)
4.2 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Forecasted Market Size by Type (2021-2026)
5 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Breakdown Data by Application (2015-2026)
5.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Historic Market Size by Application (2015-2020)
5.2 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size (2015-2026)
6.2 North America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Type (2015-2020)
6.3 North America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application (2015-2020)
6.4 North America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Country (2015-2020)
6.4.1 United States
6.4.2 Canada
7 Europe
7.1 Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size (2015-2026)
7.2 Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Type (2015-2020)
7.3 Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application (2015-2020)
7.4 Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Country (2015-2020)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
7.4.6 Nordic
7.4.7 Rest of Europe
8 China
8.1 China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size (2015-2026)
8.2 China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Type (2015-2020)
8.3 China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application (2015-2020)
8.4 China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Region (2015-2020)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 Southeast Asia
8.4.5 India
8.4.6 Australia
8.4.7 Rest of Asia-Pacific
9 Japan
9.1 Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size (2015-2026)
9.2 Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Type (2015-2020)
9.3 Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application (2015-2020)
9.4 Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Country (2015-2020)
9.4.1 Mexico
9.4.2 Brazil
10 Southeast Asia
10.1 Southeast Asia Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size (2015-2026)
10.2 Southeast Asia Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Type (2015-2020)
10.3 Southeast Asia Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application (2015-2020)
10.4 Southeast Asia Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Country (2015-2020)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 UAE
10.4.4 Rest of Middle East & Africa
11 Key Players Profiles
11.1 Qiagen NV
11.1.1 Qiagen NV Company Details
11.1.2 Qiagen NV Business Overview
11.1.3 Qiagen NV Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Introduction
11.1.4 Qiagen NV Revenue in Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Business (2015-2020))
11.1.5 Qiagen NV Recent Development
11.2 GE Healthcare
11.2.1 GE Healthcare Company Details
11.2.2 GE Healthcare Business Overview
11.2.3 GE Healthcare Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Introduction
11.2.4 GE Healthcare Revenue in Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Business (2015-2020)
11.2.5 GE Healthcare Recent Development
11.3 Agilent Technologies
11.3.1 Agilent Technologies Company Details
11.3.2 Agilent Technologies Business Overview
11.3.3 Agilent Technologies Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Introduction
11.3.4 Agilent Technologies Revenue in Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Business (2015-2020)
11.3.5 Agilent Technologies Recent Development
11.4 F Hoffman La Roche
11.4.1 F Hoffman La Roche Company Details
11.4.2 F Hoffman La Roche Business Overview
11.4.3 F Hoffman La Roche Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Introduction
11.4.4 F Hoffman La Roche Revenue in Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Business (2015-2020)
11.4.5 F Hoffman La Roche Recent Development
11.5 Foundation Medicine
11.5.1 Foundation Medicine Company Details
11.5.2 Foundation Medicine Business Overview
11.5.3 Foundation Medicine Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Introduction
11.5.4 Foundation Medicine Revenue in Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Business (2015-2020)
11.5.5 Foundation Medicine Recent Development
11.6 Thermo Fisher Scientific Inc.
11.6.1 Thermo Fisher Scientific Inc. Company Details
11.6.2 Thermo Fisher Scientific Inc. Business Overview
11.6.3 Thermo Fisher Scientific Inc. Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Introduction
11.6.4 Thermo Fisher Scientific Inc. Revenue in Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Business (2015-2020)
11.6.5 Thermo Fisher Scientific Inc. Recent Development
11.7 Leica Biosystems Nussloch GmBH
11.7.1 Leica Biosystems Nussloch GmBH Company Details
11.7.2 Leica Biosystems Nussloch GmBH Business Overview
11.7.3 Leica Biosystems Nussloch GmBH Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Introduction
11.7.4 Leica Biosystems Nussloch GmBH Revenue in Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Business (2015-2020)
11.7.5 Leica Biosystems Nussloch GmBH Recent Development
11.8 Pfizer
11.8.1 Pfizer Company Details
11.8.2 Pfizer Business Overview
11.8.3 Pfizer Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Introduction
11.8.4 Pfizer Revenue in Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Business (2015-2020)
11.8.5 Pfizer Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
